Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 23 | 2025 | 175 | 6.350 |
Why?
|
| Immunotherapy, Adoptive | 27 | 2025 | 232 | 5.540 |
Why?
|
| Antigens, CD19 | 15 | 2025 | 61 | 2.940 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 12 | 2024 | 914 | 2.260 |
Why?
|
| Lymphoma, Mantle-Cell | 4 | 2024 | 38 | 1.920 |
Why?
|
| Lymphoma, Follicular | 5 | 2024 | 74 | 1.590 |
Why?
|
| Lymphoma, B-Cell | 7 | 2025 | 110 | 1.480 |
Why?
|
| Lymphoma, Non-Hodgkin | 5 | 2023 | 267 | 1.310 |
Why?
|
| Transplantation, Autologous | 7 | 2024 | 351 | 1.200 |
Why?
|
| Standard of Care | 2 | 2024 | 65 | 0.930 |
Why?
|
| Biological Products | 5 | 2024 | 163 | 0.870 |
Why?
|
| Oncologists | 1 | 2023 | 38 | 0.860 |
Why?
|
| Receptors, Antigen, T-Cell | 8 | 2025 | 407 | 0.840 |
Why?
|
| Central Nervous System Neoplasms | 4 | 2024 | 86 | 0.780 |
Why?
|
| Neoplasm Recurrence, Local | 14 | 2024 | 1362 | 0.760 |
Why?
|
| Blood Component Removal | 1 | 2020 | 25 | 0.720 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2018 | 130 | 0.720 |
Why?
|
| Jehovah's Witnesses | 1 | 2021 | 21 | 0.720 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2018 | 194 | 0.700 |
Why?
|
| Lymphoma | 3 | 2024 | 268 | 0.690 |
Why?
|
| Transplantation Conditioning | 3 | 2021 | 378 | 0.690 |
Why?
|
| Humans | 60 | 2025 | 90640 | 0.690 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2025 | 2525 | 0.670 |
Why?
|
| Retrospective Studies | 12 | 2025 | 9330 | 0.580 |
Why?
|
| Aged | 25 | 2025 | 19424 | 0.560 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 3 | 2016 | 78 | 0.510 |
Why?
|
| Adult | 22 | 2025 | 26953 | 0.470 |
Why?
|
| Middle Aged | 23 | 2025 | 26347 | 0.460 |
Why?
|
| Graft vs Host Disease | 3 | 2023 | 362 | 0.460 |
Why?
|
| Hepatitis B virus | 1 | 2014 | 45 | 0.450 |
Why?
|
| Hepatitis B | 1 | 2014 | 76 | 0.440 |
Why?
|
| Rituximab | 5 | 2025 | 120 | 0.430 |
Why?
|
| B-Lymphocytes | 1 | 2017 | 741 | 0.420 |
Why?
|
| Geriatric Assessment | 3 | 2024 | 185 | 0.400 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 1462 | 0.380 |
Why?
|
| Remission Induction | 5 | 2024 | 745 | 0.380 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2023 | 160 | 0.370 |
Why?
|
| Male | 25 | 2025 | 42967 | 0.370 |
Why?
|
| Female | 24 | 2025 | 46894 | 0.340 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2023 | 205 | 0.340 |
Why?
|
| Cell- and Tissue-Based Therapy | 4 | 2023 | 57 | 0.330 |
Why?
|
| Prognosis | 4 | 2024 | 3813 | 0.330 |
Why?
|
| Antineoplastic Agents | 3 | 2023 | 2337 | 0.320 |
Why?
|
| Lymphoma, T-Cell | 2 | 2024 | 58 | 0.280 |
Why?
|
| T-Lymphocytes | 4 | 2021 | 1229 | 0.270 |
Why?
|
| Sarcopenia | 2 | 2016 | 13 | 0.270 |
Why?
|
| Killer Cells, Natural | 2 | 2025 | 277 | 0.260 |
Why?
|
| Treatment Outcome | 9 | 2025 | 8379 | 0.260 |
Why?
|
| Aged, 80 and over | 7 | 2025 | 6816 | 0.250 |
Why?
|
| Antibodies, Bispecific | 1 | 2024 | 30 | 0.230 |
Why?
|
| Oleic Acids | 1 | 2023 | 26 | 0.220 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2023 | 11 | 0.220 |
Why?
|
| Adolescent | 4 | 2024 | 9354 | 0.220 |
Why?
|
| Young Adult | 6 | 2025 | 6426 | 0.220 |
Why?
|
| Candidiasis | 1 | 2023 | 37 | 0.220 |
Why?
|
| Survival Analysis | 3 | 2023 | 1500 | 0.210 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2023 | 143 | 0.200 |
Why?
|
| Veterans | 4 | 2016 | 86 | 0.200 |
Why?
|
| Tumor Burden | 1 | 2023 | 316 | 0.200 |
Why?
|
| Hodgkin Disease | 1 | 2023 | 169 | 0.200 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 186 | 0.180 |
Why?
|
| 5-Methylcytosine | 1 | 2022 | 117 | 0.180 |
Why?
|
| Maximum Tolerated Dose | 2 | 2024 | 265 | 0.180 |
Why?
|
| Registries | 1 | 2025 | 812 | 0.170 |
Why?
|
| United States | 7 | 2023 | 7142 | 0.170 |
Why?
|
| Recurrence | 4 | 2024 | 1162 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2023 | 962 | 0.170 |
Why?
|
| Cladribine | 1 | 2019 | 35 | 0.170 |
Why?
|
| Carcinoma | 1 | 2023 | 438 | 0.170 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 602 | 0.170 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 60 | 0.160 |
Why?
|
| Patient Selection | 2 | 2019 | 682 | 0.160 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 354 | 0.160 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 130 | 0.160 |
Why?
|
| Neoplasms | 2 | 2023 | 3030 | 0.150 |
Why?
|
| Preoperative Care | 1 | 2019 | 400 | 0.140 |
Why?
|
| Disease Management | 1 | 2019 | 333 | 0.140 |
Why?
|
| Patient Care Team | 1 | 2019 | 286 | 0.140 |
Why?
|
| Translocation, Genetic | 1 | 2017 | 264 | 0.140 |
Why?
|
| Cyclophosphamide | 4 | 2021 | 303 | 0.130 |
Why?
|
| Obesity, Abdominal | 1 | 2016 | 8 | 0.130 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 337 | 0.130 |
Why?
|
| Body Composition | 1 | 2016 | 71 | 0.130 |
Why?
|
| Up-Regulation | 1 | 2018 | 728 | 0.130 |
Why?
|
| Stem Cell Transplantation | 3 | 2021 | 190 | 0.120 |
Why?
|
| Survivors | 1 | 2016 | 191 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 321 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 307 | 0.120 |
Why?
|
| Anthracyclines | 1 | 2015 | 34 | 0.120 |
Why?
|
| Doxorubicin | 4 | 2016 | 294 | 0.120 |
Why?
|
| Febrile Neutropenia | 1 | 2014 | 16 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 789 | 0.110 |
Why?
|
| Venous Thromboembolism | 1 | 2016 | 162 | 0.110 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2019 | 802 | 0.110 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 1142 | 0.110 |
Why?
|
| Transplantation, Homologous | 3 | 2020 | 1000 | 0.110 |
Why?
|
| Heart Failure | 1 | 2023 | 1270 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 1286 | 0.100 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 2 | 2023 | 92 | 0.100 |
Why?
|
| Time Factors | 1 | 2021 | 5366 | 0.100 |
Why?
|
| Vincristine | 3 | 2016 | 108 | 0.090 |
Why?
|
| Prednisone | 3 | 2016 | 254 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2014 | 776 | 0.090 |
Why?
|
| Antiviral Agents | 1 | 2014 | 488 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2024 | 610 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2021 | 879 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1397 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2023 | 4348 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2024 | 3698 | 0.070 |
Why?
|
| Depsipeptides | 1 | 2024 | 29 | 0.060 |
Why?
|
| Lymphoma, Extranodal NK-T-Cell | 1 | 2024 | 4 | 0.060 |
Why?
|
| Vidarabine | 1 | 2025 | 144 | 0.060 |
Why?
|
| Dairy Products | 1 | 2023 | 11 | 0.060 |
Why?
|
| Red Meat | 1 | 2023 | 10 | 0.060 |
Why?
|
| Fatty Acids, Volatile | 1 | 2023 | 32 | 0.060 |
Why?
|
| Milk | 1 | 2023 | 53 | 0.060 |
Why?
|
| Deoxycytidine | 1 | 2024 | 212 | 0.050 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2023 | 68 | 0.050 |
Why?
|
| Sheep | 1 | 2023 | 251 | 0.050 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2023 | 108 | 0.050 |
Why?
|
| Leukocyte Count | 1 | 2023 | 224 | 0.050 |
Why?
|
| Troponin | 1 | 2023 | 25 | 0.050 |
Why?
|
| Cattle | 1 | 2023 | 379 | 0.050 |
Why?
|
| Dexamethasone | 1 | 2024 | 345 | 0.050 |
Why?
|
| Cyclic AMP | 1 | 2023 | 279 | 0.050 |
Why?
|
| Melphalan | 1 | 2023 | 99 | 0.050 |
Why?
|
| Immunocompromised Host | 1 | 2023 | 142 | 0.050 |
Why?
|
| Outpatients | 1 | 2023 | 103 | 0.050 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 196 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2023 | 268 | 0.050 |
Why?
|
| Thiotepa | 1 | 2021 | 32 | 0.050 |
Why?
|
| Histiocytes | 1 | 2021 | 23 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2023 | 279 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2023 | 320 | 0.050 |
Why?
|
| Incidence | 2 | 2016 | 1594 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2021 | 154 | 0.040 |
Why?
|
| Risk Factors | 2 | 2024 | 5583 | 0.040 |
Why?
|
| Health Planning Guidelines | 1 | 2019 | 22 | 0.040 |
Why?
|
| Survival Rate | 1 | 2024 | 1895 | 0.040 |
Why?
|
| Chimerism | 1 | 2020 | 37 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 52 | 0.040 |
Why?
|
| Filgrastim | 1 | 2019 | 58 | 0.040 |
Why?
|
| Hydrazines | 1 | 2019 | 32 | 0.040 |
Why?
|
| Health Care Rationing | 1 | 2020 | 83 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 56 | 0.040 |
Why?
|
| Mice | 2 | 2023 | 11949 | 0.040 |
Why?
|
| Cytarabine | 1 | 2019 | 221 | 0.040 |
Why?
|
| Triazoles | 1 | 2019 | 107 | 0.040 |
Why?
|
| Animals | 3 | 2023 | 27715 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 526 | 0.040 |
Why?
|
| Palliative Care | 1 | 2019 | 264 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 283 | 0.040 |
Why?
|
| Steroids | 1 | 2018 | 173 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2020 | 511 | 0.030 |
Why?
|
| Abdominal Fat | 1 | 2016 | 13 | 0.030 |
Why?
|
| Biomarkers | 1 | 2023 | 1800 | 0.030 |
Why?
|
| Subcutaneous Fat | 1 | 2016 | 22 | 0.030 |
Why?
|
| Neutropenia | 1 | 2016 | 216 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 2891 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2015 | 111 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 841 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1056 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2016 | 473 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1088 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 3278 | 0.030 |
Why?
|
| Hospitalization | 1 | 2016 | 899 | 0.020 |
Why?
|
| Mutation | 1 | 2022 | 4183 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 2705 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 3486 | 0.020 |
Why?
|